aromasil has been researched along with ridaforolimus in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Awada, A; Baselga, J; Blum, JL; Ciruelos, EM; Cortes, J; Eaton, L; Ebbinghaus, S; Ewertz, M; Gause, C; Haddad, T; Im, E; Jones, MB; Mauro, D; Morales, SM; Moy, B; Pathiraja, K; Ruddy, KJ; Rugo, HS; Tan, AR; Vuylsteke, P | 1 |
| Afonso, N; Baselga, J; Blum, JL; Campone, M; Cortes, J; Denker, A; Eaton, L; Ferreira, M; Gause, CK; Im, E; Jones, MB; Mauro, DJ; Morales, SM; Musolino, A; Park, KH; Ro, J; Rugo, HS; Tan, AR; Trédan, O; Wang, Z | 1 |
2 trial(s) available for aromasil and ridaforolimus
| Article | Year |
|---|---|
A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer.
Topics: Adult; Aged; Androstadienes; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Female; Humans; Middle Aged; Protein Kinase Inhibitors; Receptors, Estrogen; Sirolimus; Stomatitis | 2017 |
A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Female; Humans; Middle Aged; Neoplasm Staging; Retreatment; Sirolimus; Treatment Outcome | 2017 |